Sit Less, Interact and Move More (SLIMM) 2 Study

Launched by SRINVASAN BEDDHU · Dec 20, 2021

Keywords

ClinConnect Summary

The Sit Less, Interact and Move More (SLIMM) 2 Study is a clinical trial aimed at helping people with chronic kidney disease and obesity reduce the time they spend sitting. Researchers have found that sitting for long periods can harm kidney function and increase the risk of diabetes and heart disease. This study, which is taking place at the University of Utah and Stanford University, is testing whether a combination of guided resistance training (to strengthen muscles) and a medication called semaglutide (which is often used for diabetes and weight loss) can help participants stick to a program that encourages them to move more and sit less.

To be eligible for this study, participants should have a specific level of kidney function, be able to perform resistance training, and have access to a smartphone or computer. The study is currently recruiting participants of all genders, aged 30 and older. Those who join can expect to receive guidance on exercising and using the medication while tracking their progress in reducing sedentary behavior. It's important to note that certain health conditions and recent medical treatments may disqualify individuals from participating, so a thorough screening will be conducted. Overall, the SLIMM 2 Study aims to find effective ways to promote movement and improve health in people with chronic kidney disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2
• • Able to perform resistance training
• • Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop
• Exclusion Criteria:
• • Type 1 Diabetes
• • History of gastroparesis or paralytic ileus
• • At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer
• • Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.
• • Previous bariatric surgery
• • Medical condition likely to limit survival to less than 1 year
• • Anticipated start of dialysis or kidney transplantation within 6 months
• • Any factors judged by the investigator or study team to likely limit adherence to interventions
• • Vulnerable populations- pregnant or incarcerated
• • Enrolled in interventional trials using drugs or devices
• • Not able to undergo informed consent
• • Recent hospitalizations or major interventional procedures done within the past 60 days
• • Known or suspected hypersensitivity to tegaderm
• • Use of any GLP-1 receptor agonist within 30 days prior to screening
• • Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure
• • Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system)
• • Presence of metastatic cancer
• • Current use of mobility aid(s)
• • Living in the same household of a participant already enrolled in the study